LeMaitre Vascular (NASDAQ:LMAT) vs. Sunny Optical Technology (Group) (OTCMKTS:SNPTF) Head to Head Survey

Sunny Optical Technology (Group) (OTCMKTS:SNPTF) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Sunny Optical Technology (Group) and LeMaitre Vascular”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunny Optical Technology (Group)	$5.33 billion	1.80	$375.45 million	N/A	N/A
LeMaitre Vascular	$219.86 million	8.65	$44.04 million	$2.32	36.11

Sunny Optical Technology (Group) has higher revenue and earnings than LeMaitre Vascular.

Analyst Ratings

This is a breakdown of current ratings for Sunny Optical Technology (Group) and LeMaitre Vascular, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunny Optical Technology (Group)	0	0	0	0	0.00
LeMaitre Vascular	0	3	4	1	2.75

LeMaitre Vascular has a consensus price target of $100.20, indicating a potential upside of 19.60%. Given LeMaitre Vascular’s stronger consensus rating and higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Sunny Optical Technology (Group).

Institutional and Insider Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 9.5% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Sunny Optical Technology (Group) has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Profitability

This table compares Sunny Optical Technology (Group) and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunny Optical Technology (Group)	N/A	N/A	N/A
LeMaitre Vascular	22.14%	14.06%	8.78%

Summary

LeMaitre Vascular beats Sunny Optical Technology (Group) on 11 of the 13 factors compared between the two stocks.

About Sunny Optical Technology (Group)

Sunny Optical Technology (Group) Company Limited, an investment holding company, engages in designing, researching, developing, manufacturing, and selling optical and optical related products, and scientific instruments. The company's Optical Components segment offers glass spherical and aspherical lenses, handset lens sets, vehicle lens sets, security surveillance lens sets, and other lens sets. Its Optoelectronic Products segment comprise handset camera modules, three dimensional optoelectronic products, vehicle modules, and other optoelectronic modules. The company's Optical Instruments segment includes microscopes and intelligent inspection equipment for testing. Its optoelectronic-related products are used in handsets, digital cameras, vehicle imaging and sensing systems, security surveillance systems, virtual reality/augmented reality, and robots, which are combined with optical, electronic, algorithm, and mechanical technologies. In addition, the company engages in the research and development of infrared and semiconductor technologies; trading of optical instruments and optoelectronics products; property leasing activities; and development, service, and consultation of technology; provision of financing services; and import and export agency services. It operates primarily in the People's Republic of China, rest of Asia, Europe, North America, and internationally. The company was founded in 1984 and is headquartered in Yuyao, China.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.